Nectin-4 : a Tumor Cell Target and Status of Inhibitor Development
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: This study aims to gather the current state of the literature about anti-Nectin-4 innovative associations in solid tumors and to investigate underlying resistance mechanisms.
RECENT FINDINGS: Antibody-drug conjugate (ADC) targeting Nectin-4 efficacy gained attention and offers a promising association with other antineoplastic drugs especially in urothelial carcinoma. The heterogeneity of Nectin-4 expression across the molecular subtypes was highlighted especially in urothelial cancers. A unique study using preclinical models demonstrated an upregulation of P-gp expression, which may explain the anti-Nectin-4 resistance mechanisms. Further studies are urgently needed to understand anti-Nectin-4 sensitivity and resistance phenomenon. The growing therapeutic associations of enfortumab vedotin offer optimistic opportunities in management and treatment of wide range of solid tumors including rare aggressive malignancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current oncology reports - 25(2023), 3 vom: 14. März, Seite 181-188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bouleftour, Wafa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidrug conjugate |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 14.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11912-023-01360-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35206627X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35206627X | ||
| 003 | DE-627 | ||
| 005 | 20231226052853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-023-01360-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM35206627X | ||
| 035 | |a (NLM)36696077 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bouleftour, Wafa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nectin-4 |b a Tumor Cell Target and Status of Inhibitor Development |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 14.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: This study aims to gather the current state of the literature about anti-Nectin-4 innovative associations in solid tumors and to investigate underlying resistance mechanisms | ||
| 520 | |a RECENT FINDINGS: Antibody-drug conjugate (ADC) targeting Nectin-4 efficacy gained attention and offers a promising association with other antineoplastic drugs especially in urothelial carcinoma. The heterogeneity of Nectin-4 expression across the molecular subtypes was highlighted especially in urothelial cancers. A unique study using preclinical models demonstrated an upregulation of P-gp expression, which may explain the anti-Nectin-4 resistance mechanisms. Further studies are urgently needed to understand anti-Nectin-4 sensitivity and resistance phenomenon. The growing therapeutic associations of enfortumab vedotin offer optimistic opportunities in management and treatment of wide range of solid tumors including rare aggressive malignancies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antidrug conjugate | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Heterogeneity | |
| 650 | 4 | |a Malignancies | |
| 650 | 4 | |a Nectin-4 | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 700 | 1 | |a Sargos, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Magne, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 25(2023), 3 vom: 14. März, Seite 181-188 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:3 |g day:14 |g month:03 |g pages:181-188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-023-01360-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 3 |b 14 |c 03 |h 181-188 | ||